Overview A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL Status: Recruiting Trial end date: 2022-12-31 Target enrollment: Participant gender: Summary The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022. Phase: Phase 2 Details Lead Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.